Neuphoria Therapeutics Inc.

NEUP

Explore Our Financial Data > Companies > Neuphoria Therapeutics Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
NEUP
CIK0001191070
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address100 SUMMIT DR, BURLINGTON, MA, 01803
Website www.neuphoriatx.com
Phone781-439-5551
CEOSpyros Papapetropoulos
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-13.59 million
Net Income$-13.51 million
Net Income to Common$-13.44 million
EPS$-18.49
View All
Balance Sheet
Cash$22.17 million
Assets$36.60 million
Liabilities$6.90 million
Common Equity$29.70 million
Liabilities & Equity$36.60 million
View All
Cash Flow Statement
Net Income$-13.51 million
Cash From Operating Activities$-16.54 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$26.79 million
Change in Cash$10.41 million
View All
Calculations
NOPAT$-12.31 million
EBITDA$-13.32 million
Price to EarningsN/A
Price to Book$0.80
ROE-45.48%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Article Link

Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees

Lynx1 Master Fund LP (together with its affiliates, "Lynx1"), the beneficial owner of 875,328 shares of common stock, par value $0.00001 per share ("Common Stock"), of Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria" or the "Company"), today announced that leading independent proxy advisory firms have recommended that shareholders support meaningful boardroom change—with Glass, Lewis & Co., LLC ("Glass Lewis") recommending that shareholders vote FOR Stephen Doberstein, Ph.D., Lyn

Article Link

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Company Urges Shareholders to Follow ISS’ Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a repo

Article Link

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today

Article Link

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

Lynx1 Master Fund LP (together with its affiliates, "Lynx1"), the beneficial owner of 875,328 shares of common stock, par value $0.00001 per share ("Common Stock"), of Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria" or the "Company"), today sent an open letter to the shareholders of Neuphoria.

Article Link